EPHA3 and posterior cortical atrophy: These findings identify EPHA3 as a novel HOC molecular target in NEPC and highlight its potential as a nutraceutical therapeutic lead for controlling this highly PCa aggressive subtype that lacks current effective therapeutic interventions.